TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

117 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • DepressionAnxiety

    Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease

    Testing whether therapy sessions can help teens and young adults with sickle cell cope with

    📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →

    The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.

    ✓ Study care freePhase 1Ages 14–21Learn more →
  • Multiple sclerosis (MS)

    Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

    Testing remibrutinib in people with relapsing multiple sclerosis who switch from ocrelizumab versus

    📍 Perseverance Research Center · Scottsdale, AZ · +39 more US sites · Get directions →

    The purpose of this Phase 3b study is to assess the efficacy, safety and tolerability of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple sclerosis (plwRMS).

    ✓ Study care freePhase 3Ages 40–70Learn more →
  • DepressionAnxiety

    Personalized Brain Stimulation to Treat Chronic Concussive Symptoms

    Testing personalized brain stimulation for ongoing concussion symptoms

    📍 UCLA · Westwood, Los Angeles, CA · Get directions →

    The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Anxiety

    Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

    Testing a single oral dose medicine versus placebo for social anxiety in adults

    📍 Vanda Investigational Site · Phoenix, AZ · +30 more US sites · Get directions →

    This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    📍 Novartis Investigative Site · Darlinghurst, New South Wales · Get directions →

    This is an open-label, multi-center, non-confirmatory study to assess the safety, disease progression, and cellular kinetics following YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascending single dose design consisting of 3 sentinel cohorts followed by an expansion cohort.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Multiple sclerosis (MS)

    Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

    Testing a modified ublituximab treatment for relapsing multiple sclerosis

    📍 TG Therapeutics Investigational Trial Site · Birmingham, AL · +34 more US sites · Get directions →

    The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1 Gadolinium (Gd)-enhancing lesions in Part A; PK in Part B along with efficacy of ublituximab as measured by T1 Gd-enhancing lesions in participants who had a suboptimal experience on prior anti-CD20 therapy in Part C. The study consists of 3 parts: Part A is single-armed and open-label, Part B is randomized, double-blind, placebo-controlled, and Part C is single-armed and open-label.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    An Open-label Study of AZD0120 in Adults With Multiple Sclerosis

    Testing safety of a new immune cell therapy in adults with multiple sclerosis

    📍 Research Site · Tucson, AZ · +8 more US sites · Get directions →

    This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • DepressionAnxiety

    ACT for Individuals With MNCD and Their Care Partners

    Testing acceptance commitment therapy for depression and anxiety in dementia

    📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →

    This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Heart / cardiovascular diseaseKidney disease

    A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

    Testing whether orforglipron changes heart outcomes in adults with heart disease and/or kidney

    📍 Instituto de Investigaciones Clínicas Bahia Blanca · Bahía Blanca, · Get directions →

    The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

    ✓ Study care freePhase 3Ages 50+Learn more →
  • DepressionAnxiety

    iTBS+D-Cycloserine for Youth Suicide

    Testing a treatment for depression and anxiety to reduce youth suicide risk

    📍 University of Calgary · Calgary, Alberta · Get directions →

    Background and Rationale: Suicide is the second leading cause of death in Canadian Emerging Adults (EAs; 18-24yrs). Current treatments for suicidal thoughts and behaviors are limited and novel treatments are required to save lives.

    ✓ Study care freePhase 2Ages 18–24Learn more →
  • Multiple sclerosis (MS)

    A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases

    Testing the safety and effects of KITE-363 in people with multiple sclerosis

    📍 Stanford Neuroscience Health Center · Palo Alto, CA · +3 more US sites · Get directions →

    This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases.

    ✓ Study care freePhase 1Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis

    Testing a CD19 CAR-T cell treatment for progressive multiple sclerosis

    📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · Get directions →

    A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • DepressionAnxiety

    Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome

    Studying how gut bacteria in pregnant people relates to depression and anxiety

    📍 Sunnybrook Health Science Center · Toronto, Ontario · Get directions →

    Perinatal depression and anxiety (PDA) are the leading causes of maternal mortality in developed countries. Women with a history of depression have a 20 fold higher risk of PDA at subsequent pregnancies.

    ✓ Study care freePhase 2Ages 18–43WomenLearn more →
  • Anxiety

    Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders

    Testing whether sertraline works better than a placebo for anxiety in children with

    📍 Alberta Children's Hospital - University of Calgary · Calgary, Alberta · Get directions →

    There are currently no approved medications for the treatment of anxiety in children and youth with neurodevelopmental disorders (NDDs), both common and rare. Sertraline, a selective serotonin reuptake inhibitor, has extensive evidence to support its use in children's and youth with anxiety but not within NDDs.

    ✓ Study care freePhase 2Ages 8–17Learn more →
  • DepressionAnxiety

    Nebulized Ketamine for the Treatment of Major Depressive Disorder

    Testing a breathing mist of ketamine to reduce symptoms of major depression

    📍 Maimonides Medical Center · Brooklyn, NY · Get directions →

    This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.

    ✓ Study care freePhase 3Ages 18–88Learn more →
  • DepressionAnxiety

    Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City

    Testing whether a phone-based program supports opioid recovery and mental health

    📍 Washington University School of Medicine · St Louis, MO · Get directions →

    The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Multiple sclerosis (MS)

    A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

    Testing a drug called BMS-986368 for muscle stiffness in multiple sclerosis

    📍 Alabama Neurology Associates · Birmingham, AL · +14 more US sites · Get directions →

    The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    Testing a drug called orelabrutinib versus placebo in people with PPMS

    📍 Arizona Neuroscience Research, LLC · Pheonix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • Anxiety

    Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

    Testing whether adding ABBV-932 to antidepressants is safe and helps adults with generalized anxiety

    📍 University of Alabama - Huntsville Regional Medical Campus /ID# 267818 · Huntsville, AL · +39 more US sites · Get directions →

    Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

    Checking if two under-the-skin versions of ocrelizumab match in the body in people with multiple

    📍 Profound Research, LLC · Carlsbad, CA · +8 more US sites · Get directions →

    The main purpose of this study is to assess the bioequivalence of ocrelizumab SC test formulation to the marketed ocrelizumab SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS). The study consists of 2 phases: a controlled phase, where participants in each group will receive one dose of test or reference formulation and a continuation phase, where all participants in both groups will receive ocrelizumab SC test formulation.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • DepressionAnxiety

    Creatine for Depressed Male and Female Methamphetamine Users

    Testing whether creatine helps depression and anxiety in people who use meth

    📍 Montana State University College of Nursing (Missoula campus) · Missoula, MT · Get directions →

    * Assess the antidepressant/anxiolytic effect of creatine in male and female methamphetamine users * Assess creatine's effect on methamphetamine use * Assess the safety of creatine in male methamphetamine users with depression

    ✓ Study care freePhase 3Ages 18–59Learn more →
  • Multiple sclerosis (MS)

    Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

    Testing whether corticosteroids change inflammation in acute MS lesions

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Multiple sclerosis (MS) affects the brain, spinal cord, and optic nerves. MS lesions can appear on the MRI (magnetic resonance imaging) scans in many ways.

    ✓ Study care freePhase 2Ages 18–120Learn more →
  • Multiple sclerosis (MS)

    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

    Comparing stem cell transplant vs best available treatment for relapsing multiple sclerosis

    📍 Stanford Multiple Sclerosis Center · Palo Alto, CA · +21 more US sites · Get directions →

    This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio.

    ✓ Study care freePhase 3Ages 18–55Learn more →
  • Heart / cardiovascular disease

    Improving Coronary Vascular Health in Women

    Testing whether blood flow in heart arteries can be improved in women with HIV

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed.

    ✓ Study care freePhase 2Ages 45–75WomenLearn more →
  • Multiple sclerosis (MS)

    Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

    Testing solriamfetol to treat tiredness from multiple sclerosis

    📍 Johns Hopkins University · Baltimore, MD · Get directions →

    Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness.

    ✓ Study care freePhase 2Ages 18–60Learn more →
  • Multiple sclerosis (MS)

    A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    Testing orelabrutinib versus placebo for people with non-active secondary progressive multiple

    📍 Arizona Neuroscience Research, LLC · Phoenix, AZ · +12 more US sites · Get directions →

    Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with non-active Secondary Progress MS.

    ✓ Study care freePhase 3Ages 18–60Learn more →
  • DepressionAnxiety

    A New Intervention to Improve Function in Veterans With Anxiety and Depression

    Testing a new treatment to improve daily functioning in veterans with anxiety and depression

    📍 Durham VA Medical Center, Durham, NC · Durham, NC · Get directions →

    Anxiety and depression symptoms occur at high rates in Veteran populations and can significantly impact function, compromising the ability to work and to successfully form and maintain valued relationships. Several other symptoms commonly occur with anxiety and depression, including poor sleep quality and chronic pain.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Heart / cardiovascular diseaseHigh blood pressure

    EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

    Testing a drug taken with empagliflozin in adults with type 2 diabetes and heart disease

    📍 Pinnacle Research Group, LLC · Anniston, AL · +39 more US sites · Get directions →

    This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • Multiple sclerosis (MS)

    A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

    Testing how a new medicine given through a vein or under the skin is handled and tolerated in people

    📍 Stanford University Medical Center · Stanford, CA · +4 more US sites · Get directions →

    The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple sclerosis (MS).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    📍 Local Institution - 0114 · Loma Linda, CA · +11 more US sites · Get directions →

    The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).

    ✓ Study care freePhase 3Ages 10–17Learn more →
  • Multiple sclerosis (MS)

    Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

    Testing whether TRX319 is safe for people with progressive multiple sclerosis

    📍 University of Kansas Medical Center · Kansas City, KS · +1 more US site · Get directions →

    The goal of this clinical trial is to treat male and female participants with two types of Multiple Sclerosis (MS) called primary progressive or secondary progressive MS. The main questions the trial aims to answer are the following: * Is TRX319 safe when administered to patients with progressive forms of MS?

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Anxiety

    📍 Servicios Especializados En Ensayos Clinicos, Seec, Sc · Mexico City, Mexico City · Get directions →

    To evaluate the superiority of cognitive behavioral therapy using the Aurora® digital medical device + conventional drug treatment, compared to conventional drug treatment alone, in reducing anxiety symptoms, as assessed by the change in the GAD-7 scale at 12 weeks of treatment, relative to baseline.

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • DepressionAnxiety

    Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

    Testing psilocybin-assisted therapy for depression and anxiety in people with advanced cancer

    💵 May compensate

    📍 MD Anderson Cancer Center · Houston, TX · Get directions →

    To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.

    ✓ Study care freePhase 2Ages 25+Learn more →
  • DepressionAnxiety

    TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors

    Testing psilocybin-assisted therapy for depression and anxiety in cancer survivors

    💵 May compensate

    📍 The University of Texas M. D. Anderson Cancer Center · Houston, TX · Get directions →

    This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Anxiety

    RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

    Testing whether a single dose injection reduces anxiety symptoms

    📍 Lighthouse Psychiatry · Gilbert, AZ · +21 more US sites · Get directions →

    The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

    ✓ Study care freePhase 2Ages 18–74Learn more →
  • Heart / cardiovascular diseaseKidney disease

    Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Testing whether sotagliflozin can slow kidney damage in type 1 diabetes

    💵 May compensate

    📍 Stanford University Medical Center · Stanford, CA · +12 more US sites · Get directions →

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because of the few studies in this population, due to concerns about the increase in risk of diabetic ketoacidosis (DKA, a serious, potentially fatal acute complication of diabetes due to the accumulation of substances called ketone bodies) observed with SGLT2i therapy in T1D.

    ✓ Study care freePhase 3Ages 18–75Learn more →
  • Multiple sclerosis (MS)

    📍 Local Institution - 0011 · Birmingham, AL · +16 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Multiple sclerosis (MS)

    Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

    Testing a medicine to reduce brain and eye tissue loss in people with multiple sclerosis

    📍 Johns Hopkins University · Baltimore, MD · +1 more US site · Get directions →

    The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).

    ✓ Study care freePhase 2Ages 18–60Learn more →
  • DepressionAnxiety

    Open-Label Psilocybin Study in Transdiagnostic Population

    Testing psilocybin for safety and symptom changes in people with depression or anxiety

    📍 Connecticut Mental Health Center - Yale School of Medicine · New Haven, CT · Get directions →

    The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer'sMultiple sclerosis (MS)

    Exploring the Utility of [18F]3F4AP for Demyelination Imaging

    Testing how an imaging tracer works in people with memory loss and multiple sclerosis

    📍 Yale University PET Center · New Haven, CT · Get directions →

    The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).

    ✓ Study care freePhase 1Ages 18–90Learn more →
  • DepressionAnxiety

    Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use

    Testing a chatbot to support people using cannabis with anxiety or depression

    📍 46 Centerra Parkway, Suite 300, Office #333S · Lebanon, NH · Get directions →

    This study tests a chatbot called Therabot-CALM to help people who use cannabis with anxiety and/or low mood. Participants will do questionnaires, try the chatbot for 4 weeks, and join virtual interviews to give feedback on how usable and helpful it feels. The goal is to see if the chatbot is acceptable to users and can improve symptoms.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • DepressionAnxiety

    Psilocybin-Assisted Therapy for Intergenerational Trauma

    Testing psilocybin-assisted therapy for depression and anxiety in children of genocide survivors

    📍 The Parsons Research Center for Psychedelic Healing · New York, NY · Get directions →

    This is an open-label psilocybin-assisted therapy study that will examine the safety and tolerability of psilocybin-assisted therapy in the offspring of genocide survivors with mood and anxiety disorders. The study will also investigate the efficacy of psilocybin-assisted therapy in reducing symptoms such as depression, anxiety and stress, as well as changes to the psychological effects of parental exposure to genocide, and changes to psychological resilience.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Anxiety

    The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

    Testing whether focused ultrasound thalamotomy can improve anxiety

    📍 The Ohio State University · Columbus, OH · Get directions →

    The purpose of this study is to evaluate the feasibility, safety, and effects on anxiety of high intensity focused ultrasound ablation (FUSA) in patients suffering from treatment-refractory focal epilepsy and anxiety. FUSA is a non-invasive neurosurgical procedure that uses ultrasound waves, sent directly through the scalp and skull, to precisely target small abnormal areas of the brain.

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Multiple sclerosis (MS)

    Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

    Testing whether special MRI using hyperpolarized carbon can predict how relapsing-remitting MS

    📍 Byers Hall · San Francisco, CA · Get directions →

    The main purpose of this study is to assess whether hyperpolarized carbon imaging in relapsing remitting multiple sclerosis (MS) patients can be used to predict response to anti-CD20 disease modifying therapy. Study procedures will include magnetic resonance imaging (MRI) assessments with a hyperpolarized pyruvate sequence, clinical assessment as well as blood markers of disease progression.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Multiple sclerosis (MS)

    A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

    Testing how well and how safely remibrutinib works in secondary progressive multiple sclerosis

    📍 Alabama Neurology Associates PC · Birmingham, AL · +32 more US sites · Get directions →

    The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

    ✓ Study care freePhase 3Ages 18–65Learn more →
  • DepressionAnxiety

    Cannabis for Palliative Care in Cancer

    Testing cannabis for symptom relief and side effects in cancer patients

    📍 Anschutz Health Sciences Building · Aurora, CO · Get directions →

    Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required.

    ✓ Study care freePhase 2Ages 25+Learn more →
  • DepressionAnxiety

    Pramipexole to Enhance Social Connections

    Testing whether pramipexole improves social connectedness in adults with anxiety or depression

    📍 University of California, San Diego · San Diego, CA · +1 more US site · Get directions →

    This study seeks to understand if the medication pramipexole improves social connectedness and functioning in adults (ages 18-50) who experience anxiety or depression. The study plans to enroll 108 participants total across two sites (University of California San Diego and New York State Psychiatric Institute).

    ✓ Study care freePhase 2Ages 18–50Learn more →
  • Anxiety

    Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

    Testing a marijuana-based compound to treat anxiety in autistic adults

    📍 Southwest Autism Research and Resource Center · Phoenix, AZ · Get directions →

    The goal of this clinical trial is to learn if drug ABC works to treat severe asthma in adults. It will also learn about the safety of drug ABC.

    ✓ Study care freePhase 2Ages 18–45Learn more →
  • DepressionAnxiety

    Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)

    Testing a cognitive training program to see brain and thinking changes in people with depression or

    📍 UC San Diego · San Diego, CA · Get directions →

    The proposed project aims to test the cognitive and neural effects of a cognitive training in a sample of individuals seeking treatment for anxiety, depression, or traumatic stress symptoms. Participants will be randomly assigned to one of two groups.

    ✓ Study care freePhase 2Ages 21–55Learn more →
  • DepressionAnxiety

    Modulating Exercise Dosage to Improve Concussion Recovery

    Testing whether a higher amount of aerobic exercise helps concussion recovery

    📍 University of Colorado Denver · Aurora, CO · +2 more US sites · Get directions →

    Aerobic exercise has emerged as an effective treatment to reduce sport-related concussion symptom severity, yet existing work lacks rigor regarding the precise exercise volume and intensity required to elicit therapeutic effects, how exercise can alter concussion-related pathophysiology, and whether exercise can prevent the development of secondary sequelae. Our objective is to examine if a high dose exercise program (higher volume than currently prescribed at an individualized, safe intensity level) initiated within 14 days of concussion results in faster symptom resolution, altered physiological function, or reduced secondary sequalae.

    ✓ Study care freePhase 2Ages 13–18Learn more →
  • Heart / cardiovascular diseaseLupus (SLE)

    The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

    Testing whether anifrolumab improves blood vessel risk markers in lupus

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. This can increase the risk of heart attacks or stroke.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Prevention of Progression of Prediabetes, Obesity and CV Risk

    Testing ways to stop prediabetes and obesity from getting worse

    💵 May compensate

    📍 University of Texas Health Science Center at San Antonio · San Antonio, TX · Get directions →

    The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • DepressionAnxiety

    Cannabidiol and Older Adult Cannabis Users

    Testing how hemp CBD and THC affect mood and anxiety in older adults

    📍 University of Colorado at Boulder · Boulder, CO · Get directions →

    Cannabis use increased 10 fold among adults over the age of 65 between 2014 and 2016 but very little data exists on the extent of their harmful effects on health and behavior. The overarching goal of this project is to test a novel harm reduction strategy in which older individuals who seek to use cannabis for pain, anxiety or mood problems (depression/anxiety) will be randomly assigned to one of three conditions in an 8 week randomized controlled trial: hemp-derived CBD+THC, hemp-derived CBD-THC, or placebo.

    ✓ Study care freePhase 2Ages 60+Learn more →
  • DepressionAnxiety

    Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV

    Testing whether pregnenolone pills affect brain function and depression in people with HIV

    💵 May compensate

    📍 Massachusetts General Hospital · Boston, MA · Get directions →

    This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications.

    ✓ Study care freePhase 2Ages 18–85Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    Testing whether maridebart cafraglutide lowers heart risks in people with heart disease and obesity

    📍 Alliance For Multispecialty Research - Daphne · Daphne, AL · +39 more US sites · Get directions →

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    ✓ Study care freePhase 3Ages 45–99Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    Testing maridebart cafraglutide with standard care to reduce heart failure events in obese people

    💵 May compensate

    📍 University of Alabama Saint Vincent's Birmingham · Birmingham, AL · +39 more US sites · Get directions →

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part trial with a double-blind period and an open-label extension (OLE).

    ✓ Study care freePhase 3Ages 18–99Learn more →
  • Multiple sclerosis (MS)

    Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

    Testing metformin alone or with other treatment in older people with multiple sclerosis

    📍 UBMD Neurolgy · Buffalo, NY · Get directions →

    The goal of the study is to learn about treating older people with multiple sclerosis (MS) with metformin. Metformin may be used as a single therapy or as an add-on therapy.

    ✓ Study care freePhase 2Ages 55–75Learn more →
  • Obesity / overweightHeart / cardiovascular disease

    A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    Testing how well NNC0487-0111 works versus placebo in heart failure with excess body weight

    📍 Advanced Cardiovascular, LLC · Alexander City, AL · +39 more US sites · Get directions →

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight.

    ✓ Study care freePhase 3Ages 18+Learn more →
  • DepressionAnxiety

    Family Acceptance Project Online (Pilot RCT)

    Testing an online program to reduce depression and anxiety in LGBTQ youth by improving family

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    Research shows that sexual and gender minority youth (SGMY) experience high rates of mental health problems and other challenges (e.g., social, academic). A major factor that leads to these challenges is family rejection (family behaviors and reactions that minimize, deny, ridicule and attempt to prevent or change a child's sexual orientation, gender identity and gender expression).

    ✓ Study care freePhase 2Ages 14+Learn more →
  • Anxiety

    Gaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety

    Testing a music-based therapy added to CBT to treat anxiety in children

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: Anxiety disorders are becoming more common among children and teenagers. Anxiety can lead to long-term physical and mental problems, such as depression.

    ✓ Study care freePhase 2Ages 8–17Learn more →
  • Showing the first 60 of 117. Add filters or a location to narrow down.